Advaxis enters into Collaboration with the University of British Columbia
North Brunswick, NJ – November 8, 2010 –Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has entered into a structured collaboration with the laboratory of Dr. Tobias Kollmann at the University of British Columbia (UBC) to develop live attenuated Listeria vaccines for the treatment of infectious disease, and for new forms of delivery of Listeria vaccines.
The same immune stimulating properties that are under development at Advaxis to develop live Listeria vaccines as safe and effective therapies for the treatment of cancer also may have application for the treatment of infectious disease. Dr. Kollmann is an immunologist and neonatal vaccinologist who has published extensively on the use of Listeria vaccines as potential therapeutic agents for the treatment of childhood diseases.
Under the terms of this collaboration, Dr. Kollmann will use Advaxis proprietary Listeria vaccine vectors for the development of novel infectious disease applications, and will employ a post-doctoral fellow who will be dedicated to the creation and assessment of novel infectious disease vaccines and new forms of delivery of live attenuated Listeria vaccines.
About The Laboratory of Dr. Tobias Kollmann
Dr. Tobias Kollmann MD Ph.D is an Assistant Professor in the Division of Infectious and Immunological Diseases, Department of Pediatrics at the University of British Columbia’s Child and Family Research Institute. According to Dr. Kollmann, “The immune system in early life is not so much less responsive, but rather responds differently as compared to the immune system of an adult. Listeria appears to activate the newborn’s immune system in just the right way, inducing long-lived protection from infection even after only one single dose given around birth.” The Kollmann lab has published several articles on the use of live attenuated vaccines for the prevention of infectious disease in neonates, which is currently an area of urgent but unmet medical need.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research – UK and the Department of Homeland Security. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.
Please visit the Company’s website: advaxis.com
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
For Further Information:
|Conrad F. Mir||Diana Moore|
|Advaxis, Incorporated||Advaxis, Incorporated|
|732.545.1590 (Office)||732.545.1590 (Office)|
|732.545.1084 (FAX)||732.545.1084 (FAX)|